PAR 4.00% 26.0¢ paradigm biopharmaceuticals limited..

Efficacy and safety of pentosan polysulfate sodium in people...

  1. 4,109 Posts.
    lightbulb Created with Sketch. 1425
    Efficacy and safety of pentosan polysulfate sodium in people with symptomatic knee osteoarthritis and dyslipidaemia: protocol of the MaRVeL trial
    https://pubmed.ncbi.nlm.nih.gov/38777590/

    ACTRN12621000654853
    A Double-Blind, RandoMised, Placebo-Controlled Study to Assess the
    Efficacy and Safety of oRal deliVery of sodium Pentosan Polysulfate (PPS)
    compared to placebo in participants with symptomatic kneE osteoarthritis
    (OA) and dysLipidemia (MaRVeL Study)

    https://anzctr.org.au/Trial/Registration/TrialReview.aspx?ACTRN=12621000654853

    Name
    Arthropharm Pty Ltd
    https://www.arthropharm.com.au/
 
watchlist Created with Sketch. Add PAR (ASX) to my watchlist
(20min delay)
Last
26.0¢
Change
0.010(4.00%)
Mkt cap ! $91.06M
Open High Low Value Volume
25.0¢ 26.0¢ 25.0¢ $36.40K 143.5K

Buyers (Bids)

No. Vol. Price($)
1 40816 24.5¢
 

Sellers (Offers)

Price($) Vol. No.
26.0¢ 44646 4
View Market Depth
Last trade - 16.10pm 17/09/2024 (20 minute delay) ?
PAR (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.